Apatinib Mesylate +SHR-1210
CancerIHCAMS-HCC-SHR1210
Phase 2 other active
Quick answer
Apatinib Mesylate +SHR-1210 for Hepatocellular Carcinoma is a Phase 2 program (other) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chinese University of Hong Kong
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active